Search

Search Constraints

You searched for: Author/Creator Kahatt, Carmen

Search Results

1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. (December 2020)

2. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. (26th October 2018)

3. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Issue 4 (April 2016)

4. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Issue 4 (April 2016)

5. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Issue 1 (January 2023)

6. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th November 2021)

7. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. Issue 11 (5th October 2021)

8. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial. (August 2017)

9. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. Issue 12 (15th October 2019)

10. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Issue 5 (May 2020)